The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston.
² Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.

Comment

Farhad Ravandi et al. JAMA Oncol. 2021.

. 2021 May 1;7(5):784-785.

doi: 10.1001/jamaoncol.2021.0128.

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston.
² Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.

No abstract available

Comment on

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Short NJ, et al. JAMA Oncol. 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600. JAMA Oncol. 2020. PMID: 33030517 Free PMC article.
The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making.
Przepiorka D, de Claro RA, Pazdur R. Przepiorka D, et al. JAMA Oncol. 2021 May 1;7(5):784. doi: 10.1001/jamaoncol.2021.0122. JAMA Oncol. 2021. PMID: 33764395 No abstract available.